CEO of BioMarin Pharmaceutical Inc. (BMRN, Financial) Jean Jacques Bienaime sells 2,000 shares of BMRN on 11/08/2010 at an average price of $25.78 a share.
Biomarin Pharmaceutical Inc. has a market cap of $2.63 billion; its shares were traded at around $25.74 with a P/E ratio of 1287 and P/S ratio of 8.1.
BMRN is in the portfolios of Richard Aster Jr of Meridian Fund, Columbia Wanger of Columbia Wanger Asset Management, PRIMECAP Management, RS Investment Management, Bruce Kovner of Caxton Associates, Pioneer Investments, George Soros of Soros Fund Management LLC, Chuck Royce of Royce& Associates, Chuck Royce of Royce& Associates.
Biomarin Pharmaceutical Inc. has a market cap of $2.63 billion; its shares were traded at around $25.74 with a P/E ratio of 1287 and P/S ratio of 8.1.
BMRN is in the portfolios of Richard Aster Jr of Meridian Fund, Columbia Wanger of Columbia Wanger Asset Management, PRIMECAP Management, RS Investment Management, Bruce Kovner of Caxton Associates, Pioneer Investments, George Soros of Soros Fund Management LLC, Chuck Royce of Royce& Associates, Chuck Royce of Royce& Associates.
CEO Recent Trades:
- Sell: CEO Jean Jacques Bienaime sold 7,500 shares of BMRN stock on 11/03/2010 at the average price of 25.54. Jean Jacques Bienaime owns at least 93,567 shares after this. The price of the stock has increased by 0.78% since.
- Sell: CEO Jean Jacques Bienaime sold 1,000 shares of BMRN stock on 09/08/2010 at the average price of 22.22. Jean Jacques Bienaime owns at least 95,067 shares after this. The price of the stock has increased by 15.84% since.
- Sell: CEO Jean Jacques Bienaime sold 4,000 shares of BMRN stock on 09/02/2010 at the average price of 20.97. Jean Jacques Bienaime owns at least 95,067 shares after this. The price of the stock has increased by 22.75% since.
- Sell: CEO Jean Jacques Bienaime sold 3,000 shares of BMRN stock on 08/30/2010 at the average price of 20.71. Jean Jacques Bienaime owns at least 99,067 shares after this. The price of the stock has increased by 24.29% since.
- Sell: CEO Jean Jacques Bienaime sold 3,000 shares of BMRN stock on 08/30/2010 at the average price of 20.71. Jean Jacques Bienaime owns at least 99,067 shares after this. The price of the stock has increased by 24.29% since.
CFO Recent Trades:
- Sell: SVP, CFO Jeffrey H Cooper sold 28,750 shares of BMRN stock on 10/29/2010 at the average price of 25.32. Jeffrey H Cooper owns at least 26,486 shares after this. The price of the stock has increased by 1.66% since.
- Sell: SVP, CFO Jeffrey H Cooper sold 15,209 shares of BMRN stock on 10/25/2010 at the average price of 24. Jeffrey H Cooper owns at least 26,486 shares after this. The price of the stock has increased by 7.25% since.
- Sell: SVP, CFO Jeffrey H Cooper sold 6,000 shares of BMRN stock on 09/13/2010 at the average price of 22.85. Jeffrey H Cooper owns at least 26,486 shares after this. The price of the stock has increased by 12.65% since.
Directors and Officers Recent Trades:
- Sell: SVP, General Counsel George Eric Davis sold 10,371 shares of BMRN stock on 11/04/2010 at the average price of 25.83. George Eric Davis owns at least 27,901 shares after this. The price of the stock has decreased by 0.35% since.
- Sell: SVP, General Counsel George Eric Davis sold 10,371 shares of BMRN stock on 11/04/2010 at the average price of 25.83. George Eric Davis owns at least 27,901 shares after this. The price of the stock has decreased by 0.35% since.
- Sell: EVP, Technical Operations Robert Baffi sold 2,000 shares of BMRN stock on 11/03/2010 at the average price of 25.24. Robert Baffi owns at least 67,713 shares after this. The price of the stock has increased by 1.98% since.
- Sell: EVP, Technical Operations Robert Baffi sold 2,000 shares of BMRN stock on 11/03/2010 at the average price of 25.24. Robert Baffi owns at least 67,713 shares after this. The price of the stock has increased by 1.98% since.
- Sell: EVP, Chief Medical Officer Henry J Fuchs sold 2,435 shares of BMRN stock on 11/01/2010 at the average price of 25.76. Henry J Fuchs owns at least 31,000 shares after this. The price of the stock has decreased by 0.08% since.
